Unparalleled Precision of SPEAR UltraDetect™ Immunoassays with Homogeneous Format: GFAP and NF-L

The Importance and Challenges of Measuring Neurological Biomarkers

Accurate biomarker quantification, combining high sensitivity and precision, is vital for neurological research. Quantifying biomarkers such as GFAP, indicative of astrocytic activation, and NF-L, reflecting axonal damage, enables informed disease management and timely intervention.

Detecting Low-Abundance Biomarkers Consistently

This requires not only detecting low-abundance biomarkers but doing so consistently and reproducibly over time and across samples. While conventional ultra-sensitive platforms have enabled new discoveries, they have historically struggled with assay precision and variability—especially in blood matrices where concentrations of neuro biomarkers are typically much lower than in CSF. 

Limitations in Tracking Subtle Biomarker Shifts

These limitations compromise the accurate tracking of modest but meaningful biomarker shifts, which are essential for detecting early disease signals, evaluating therapeutic response, and monitoring longitudinal disease progression.

How does the SPEAR UltraDetect™ Platform Improve Analytical Performance?

• Delivers remarkably low coefficients of variation even at lowest concentrations.
• Deliver ultra-sensitivity with high precision, enabling reproducible detection of subtle, meaningful changes.
• Establishes a new benchmark for analytical performance in neurological biomarker analysis.

Learn more about SPEAR UltraDetect Assays distributed by Bio-Techne.